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CHAPTER I.GENERAL INTRODUCTION 
Antimicrobials have been used in swine diets for decades (Boehm, 1975). 
Antimicrobial agents are given to food animals as therapy for an infection or, in the absence 
of disease, for the subtherapeutic purpose of increased rate of gain and improved feed 
efficiency (Gorbach et al., 2001; Stahly et al., 1980). The increasing use of subtherapeutic 
antimicrobials in food-animals may create environments that select for antibiotic-resistant 
pathogens. The emergence of human pathogenic antibiotic-resistant strains of bacteria has 
led to restrictions in their use (White et al., 2001). Currently a federal bill to ban the use of 
penicillin, tetracycline, and fluoroquinolones in livestock feed is being considered. Drug 
manufacturers must prove to the US Food and Drug Administration that use of these 
antibiotics does not result in antibiotic-resistant strains of bacteria. 
Increasing pressures to curb use of antibiotics has lead to a growing interest in 
alternatives. Botanicals could provide producers with alternatives to antimicrobials. Herbal 
remedies have been used in swine diets because of their natural stimulation of the immune 
system and enhanced performance. Extracts from Echinacea have been shown to have 
nonspecific immunostimulatoryproperties in vitro (Bauer and Wagner, 1991). Schulte et al., 
(1967) isolated polyacetylene compounds with bacteriostatic activity from E. purpurea. 
Preliminary work with Echinacea fed to pigs showed improved feed efficiency and daily gain 
when compared to a control diet (Holden and McKean, 2000). The use of Echinacea 
purpurea as an effective alternative growth promotant for growing swine needs further 
investigation. 
Porcine reproductive respiratory syndrome virus (PRRSV) causes significant 
economic losses worldwide in the swine industry. The disease is characterized by abortions 
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and infertility in breeding stock, weak or dead pigs, and increased mortality in young pigs 
(Zimmerman, 1997). PRRSV allows secondary opportunistic pathogens to cause disease in 
infected pigs (Feng et al., 2001). Ineffective vaccines have been introduced to the swine 
industry in hopes of prevention and control of the virus. 
Echinacea is used as a non-specific immune stimulator. Non-specific effects include 
phagocytosis (Strotzem et al., 1992), cytokine production (Burger et al., 1997), natural killer 
cell activity (See et al., 1997). Rehman et al., (1999) showed an increase in primary and 
secondary IgG response in mice treated with Echinacea. These antiviral properties of 
Echinacea purpurea could provide resistance to PRRSV and diminish the opportunistic 
secondary infections. 
Few scientific studies have assessed the efficacy ofEchinacea in vivo with varying 
results (Melchart et al., 1998; Turner et al., 2000; Grimm and Muller, 1999). Less research 
has been done with the effects of Echinacea on performance in swine (Holden and McKean, 
2000). No studies have involved pigs as an animal model in assessing the efficacy of 
Echinacea. Inoculating animals with PRRSV provides the opportunity to observe the 
immunostimulatory properties of Echinacea. Our objectives were to determine the 
effectiveness of Echinacea purpurea with a defined chemical profile on growth performance 




This thesis is divided into a general introduction, literature review with 
references, a paper with references, and a summary. The following paper was prepared for 
submission to the Journal of Animal Science. 
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CHAPTER 2. LITERATURE REVIEW 
Immunity 
The immune system is an adaptive defense system protecting vertebrates from 
pathogenic organisms. There are two types of defenses against invading pathogens, the 
innate and adaptive immunity. This is a general overview of the immune system with 
specific references to swine. 
Innate Immunity 
Innate immunity is a nonspecific mechanism providing the first line of resistance to 
an invading pathogen (Goldsby et al., 2000). The major elements are anatomical, 
physiological, phagocytic, and inflammatory barriers. 
Anatomical barriers 
Anatomical barriers are skin and mucous membranes. The mechanical barrier and 
low pH of the skin inhibit entry and reproduction of microbes. Mucus traps foreign 
microorganisms and cilia propel them out of the body. 
Physiological barriers 
Physiological barriers in the pig are temperature, pH, and soluble factors. The normal 
body temperature helps to inhibit growth of organisms. Fever responses retard the 
reproduction and growth of pathogens (Goldsby et al., 2000). Many ingested 
microorganisms are unable to overcome the acidic environment of the stomach. Soluble 
factors include acute phase proteins, lysozyme, interferon (INF), and the complement system. 
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Proteins in plasma named acute phase proteins increase in concentration in response 
to mediators such as interleukin- I, interleukin-6 and tumor necrosis factor (TNF), that are 
released as a result of infection or injury (Mims et al., 1998). These acute phase proteins can 
help fix complement, inhibit bacterial proteases, opsonize bacteria, transport proteins, bind 
hemoglobin, and affect blood pressure. Lysozyme, a hydrolytic enzyme found in mucous 
secretions and tears, splits the peptidoglycan wall of bacteria causing them to lyse (Goldsby 
et al., 2000). Interferons are antimicrobial cytokines that interfere with neighboring cells 
inhibiting viral replication. There are three types of INFs alpha, beta, and gamma and these 
interact with specific receptors on most cells causing the release of at least two enzymes, a 
protein kinase and a 2' ,5 '-oligoadenylate synthetase. The enzymes inhibit viral RNA 
synthesis prohibiting protein synthesis (Mims et al., 1998). 
Complement system 
Biological activity of the complement system is influenced both by innate and 
adaptive immunity. The basic functions of complement are lysis of cells, bacteria, and 
viruses. The functions of complement are carried out by opsonization of antigens which 
facilitates the phagocytosis of pathogens, and triggering of inflammation and secretion of 
molecules that amplify specific immune responses. Initial activation of complement 
components triggers a highly amplified regulated cascade. Many components are zymogens 
(inactive proteins) activated by removal of an inhibitory fragment. Complement components 
are denoted by numerals (Cl-C9), letter symbols (factor B), or names (C3 convertase). The 
peptide fragments resulting from cleavage are designated small letters (C3c). Fragments 
interact with one another to form functional complexes. Complexes with enzymatic activity 
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are labeled with a bar over the letter (C4b2a) (Goldsby et al., 2000). The formation of the 
membrane attack complex can be accomplished either by the classical pathway, the 
alternative pathway, or the lectin pathway. 
Classical Pathway 
The complement activation by the classical pathway begins with the formation of 
antigen-antibody complexes. The binding induces conformational changes in the Fe portion 
of the antibody exposing a binding site for the Cl component. Binding activates Cl 
converting it into an esterase. The activated Cl component splits off a peptide from C4 and 
C2. C4 splits to C4a and C4b. C2 splits to C2a and C2b. C4b2a acts as C3 convertase 
splitting C3 into C3a and C3b. C3b binds to C4b2a to form a trimolecular complex CS 
convertase. The C3b component binds to CS to change its configuration while C4b2a splits 
CS into CSa and CSb. CSb attaches to C6 and initiates the membrane-attack complex 
(MAC). C3a, C4a, CS a are anaphylatoxins, or mediators of inflammation, causing capillary 
dilation and exudation of plasma proteins, and chemotactic attraction of polymorphs 
(Goldsby et al., 2000) (Mims et al., 1998). 
Alternative pathway 
The alternate pathway is a component of the innate immune system. Serum C3 
undergoes spontaneous hydrolysis to yield C3a and C3b. C3b can bind to surface antigens 
on foreign cells. Once bound to the membrane C3b can bind the serum protein factor B. The 
binding of factor B exposes a bind site for factor D to form a complex. Factor D splits factor 
B and generates C3bBb complex called C3 splitting enzyme. This C3 convertase can cleave 
new molecules of C3 to give C3a and C3b. This is analogous to the C4b2a complex in the 
8 
classical pathway. The formation of CS convertase leading to the MAC in the alternate 
pathway is identical to the classical pathway (Goldsby et al., 2000) (Mims et al., 1998). 
Lectin pathway 
Lectins are proteins that bind to a carbohydrate. The lectin pathway is activated by 
the binding ofmannose-binding lectin (MBL) to mannose residues on glycoproteins on the 
swface of microorganisms (Goldsby et al., 2000). After MBL binds to a carbohydrate on the 
swface of a pathogen serine protease binds to it. This association causes the splitting and 
activation of C4. Activating C4 and C2 components forms a CS convertase and the initiation 
of the terminal sequence which is formation of the membrane attack complex (MAC). 
CSb attaching to the surface of the target cell provides the binding sites for the 
membrane attack complex. The binding of C6, C7, and C8 to C5b forms a complex capable 
of causing a conformational change in the terminal component C9 (Mims et al., 1998). The 
final step is the binding and polymerization of C9 to the C5b678 complex. This MAC 
displaces the membrane phospholipids forming a transmembrane channel. Ions and small 
molecules diffuse causing a net influx of sodium and frequent lysis. 
Phagocytic barriers 
Phagocytic cells are an important innate defense mechanism in the ingestion of 
extracellular material during phagocytosis. The major groups of phagocytic cells are 
neutrophils, monocytes and dendritic cells. These cells do not produce antigen-binding 
receptors and lack specificity and memory. The majority of lymphocytes are large granular 
lymphocytes called natural killer cells (NK). NK cells provide defense against tumor cells 
and cells infected with some viruses. NK cells recognize target cells due to the production of 
9 
antiviral or antitumor antibodies. NK cells recognize these antibodies and destroy the 
targeted cells. This is known as antibody-dependent cell-mediated cytotoxicity (ADCC) 
(Goldsby et al., 2000). The mononuclear phagocytic system consists of monocytes 
circulating in the blood and macrophages in the tissues. Monocytes circulate in the blood 
before differentiating into tissue macrophages. Macrophages perform different functions in 
different tissues and are named according to their tissue. Pulmonary intravascular 
macrophages are responsible for the clearance of blood-borne bacteria and particulates in 
pigs (Staub, 1989). The liver performs the removal of particles in pigs. Phagocytosis of 
antigens, cytokine secretion, mediators in the inflammatory response, and components of 
bacterial cell walls are ways macrophages can be activated. Activated macrophages exhibit 
greater phagocytic activity, increased secretion of inflammatory mediators, and an increased 
ability to activate cells of the adaptive immune system (Goldsby et al., 2000). 
Phagocytosis is initiated by chemotaxis, a process in which macrophages are attracted 
to the target cell by chemical substances. The macrophage physically close to the target cell 
can attach to an antigen on the membrane. An actin and myosin contractile system is 
activated causing membrane protrusions called pseudopodia. The engulfing of the pathogen 
by the pseudopodia creates a structure called a phagosome. The phagosome moves toward 
the cell interior where it fuses with a lysosome to form a phagolysosome (Goldsby et al., 
2000). Granules excrete lysozyme into the phagolysosome. The pathogen is destroyed by 
oxygen-independent and oxygen-dependent killing mechanisms. The material is excreted 
from the cell in a process called exocytosis. 
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Inflammatory barriers 
Invading pathogens can cause an acute inflammatory response in a host tissues. 
Chemical mediators initiate the inflammatory response causing vasodilatation and an 
increase in capillary permeability. This allows the accumulation of fluid high in plasma 
proteins including complement. The swelling of the tissues is called edema. These· 
mediators up-regulate intercellular molecules which bind specific phagocytes to the walls of 
capillaries called margination. The emigration of phagocytes between capillary-endothelial 
cells into the tissues is called diapedesis (Goldsby et al., 2000). The chemotactic factors lead 
the phagocytes to the pathogens where the presence of complement causes opsonization. 
Adaptive immunity 
Adaptive or specific immunity differs from innate immunity by being antigen 
specific, demonstrating great diversity, having memory and be able to recognize sel£'non-
self. Antigenic specificity and diversity allows the immune system to recognize and produce 
antibodies to billions of antigens. Once exposed to an antigen the immune system can 
recognize the intruder and produce a faster response. The immune system only responds to 
nonself antigens, a trait that is necessary for existence. The two major types of cells that 
make up the adaptive immune system are lymphocytes and antigen-presenting cells. 
Lymphocytes 
The populations of lymphocytes are B lymphocytes (B cells) and T lymphocytes (T 
cells). B cells mature within the bone marrow and express an antigen-binding receptor. 
When an antigen attaches to the receptor on a naYve B cell, the B cell proliferates, 
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differentiates, and produces antibodies. The B cell differentiates into memory B cells and 
effector B cells. The memory B cell expresses the same antigen-binding receptor as its 
parent cell but has a longer life span. Effector B cells or plasma cells produce antibodies that 
are excreted in large amounts. Antibodies are immunoglobulins consisting of two identical 
light and two identical heavy polypeptide chains linked together by disulfide bonds. There 
are two portions to the antibody the Fab and the Fe regions. The Fab is the recognition site 
enabling it to bind to antigens. The Fe portion is the backbone capable of some secondary 
biological functions. There are five major classes ofimmunoglobulins in the human IgG, 
IgA, IgM, IgD, and IgE. Pigs differ from humans in that they do not posses IgD (Blecha, 
2001). 
T lymphocytes or T cells are produced in bone marrow and mature in the thymus 
gland. T lymphocytes defend against microorganisms that live within cells and are 
unaffected by antibodies. T cells can only recognize antigens that are bound to proteins 
called major histocompatibility complex (MHC) molecules (Goldsby et al., 2000). There are 
two types ofMHC molecules class I MHC molecules and class II MHC molecules. Class I 
are found on nearly every cell in the body. Class II MHC molecules are expressed only by 
antigen-presenting cells. Intracellular enzymes fragment microorganisms and their peptides 
are associated with a MHC. T lymphocytes that come in contact with an antigen combined 
MHC molecule are activated. The activated T lymphocytes proliferate and differentiate 
(Goldsby et al., 2000). There are two types ofT cells: T helper (TH) cells and T cytotoxic 
(Tc) cells. T helper and T cytotoxic cells can be distinguished from one another by the 
presence of CD4 or CDS glycoproteins. TH cells display CD4 and Tc cells display CDS 
glycoproteins. Porcine T lymphocyte populations appear to be the most heterogeneous of all 
12 
mammalian species (Blecha, 2001). TH cells interact with l\1HC class II molecules, are 
activated, and secrete cytokines. Cytokines are growth factors that activate cells responsible 
for immune responses. Tc cells interact with MHC class I molecules and exhibit cytotoxic 
activity (Mims et al., 1998). 
Antigen presenting cells 
Antigen presenting cells are specialized cells that express class II l\1HC molecules on 
their membranes. These cells deliver a signal that is necessary for TH cell activation 
(Goldsby et al., 2000). Antigen presenting cells first internalize the pathogen by 
phagocytosis and then display the antigen on the membrane. 
Adaptive and innate immunity are not independent of one another. Phagocytic cells 
can activate the adaptive immune response. Soluble factors can initiate the lysis of 
pathogens and recruitment of cells that participate in the immune response. The 
inflammatory response attracts cells of the innate and adaptive immune systems. The innate · 
and adaptive immune systems work together in unison to eradicate foreign intruders. 
The immune enhancing effects of Echinacea are discussed in the Echinacea section. 
Porcine Reproductive and Respiratory Syndrome 
Porcine reproductive respiratory syndrome virus (PRRSV) causes significant 
economic losses worldwide in the swine industry. A 1990 serologic study showed that 
82.7% of U.S. herds tested were infected with PRRS virus (Bautista et al., 1993). The PRRS 
virus consists of a linear, non-segmented, positive sense, single-stranded RNA genome. The 
virus is of the genus Arterivirus, family Arterivirdae, and order Nidovirales (Cavanaugh, 
1997). The disease is characterized by abortions and infertility in breeding stock, weak or 
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dead pigs, and increased mortality in young pigs (Zimmerman et al., 1997). The clinical 
symptoms vary among herds infected with PRRSV. Subclinical infections to chronic disease 
outbreaks are observed. In severe outbreaks, secondary opportunistic pathogens can cause 
respiratory disease in infected pigs. PRRSV infects macrophages in the pig (Yoon et al., 
1996). PRRSV can be isolated from the lungs, spleen, and other lymph tissues. Virus 
isolation of the PRRS virus is performed on MARC-145 cells. Kim et al. (1993) reported 
that a PRRS replication cycle was 48 to 72 hours. Benfield et al., (1994) demonstrated that 
the virus is present in the blood stream as early as 12 h post inoculation. Viral concentrations 
peak between four to eight days post-infection and can continue for weeks (Greiner et al., 
2001 ). The virus persists in spite of active humoral immune response by low level 
replication and eventually clears the body in the majority of animals by 150 days post 
inoculation (Allende et al., 2000). This chronic exposure stimulates the immune system 
negatively impacting performance. Infection can occur in the presence of an active immune 
response. IgM and IgG are actively secreted in response to the virus. The 26-kDa envelope 
protein is important in terms of virus neutralization, although antibody-dependent 




Ecltjnacea was used medicinally by the native Americans against illnesses more than 
any other plant (Gilmore, 1919). The roots were the most frequently used part of the plant 
(Bauer and Wagner, 1991). Echinacea is native to the prairies of the U.S. Midwest and the 
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Upper South. Echinacea species generally grow in well-drained soils and are drought 
tolerant. Roots ofEchinacea are harvested in the fall at three years of age preventing woody 
roots (Foster, 1992). Yields of 1,200 pounds of dried root per acre can be expected (Miller, 
1997). 
The use of botanicals as medicinal remedies has increased dramatically in recent 
years. Herbal sales exceeded 3.3 billion dollars in 1999 (Popovich, 2000). Sales of herbal 
products have increased exponentially with major projected growth rates for many years. 
Echinacea is one of the most prevalent herbs used and is first among perceived efficacy of 
herbs (Harnack et al., 2001 ). Echinacea taxonomy includes nine species and three species 
are commercially available. They are Echinacea purpurea, Echinacea angustifolia, and 
Echinacea pallida. E. purpurea is commonly known as purple coneflower. 
Chemical constituents 
Chemical constituents of Echinacea are numerous and species dependent. Echinacea 
products vary widely in chemical composition making standardization difficult. 
Echinacoside, cichoric acid (2,3-O-dicaffeoyltartaric ), and chlorogenic acid are caffeic acid 
derivatives found in Echinacea (Bauer and Wagner, 1991). Echinacea purpurea contains 
little to no echinacosides. Echinacea angustifolia contains only traces of cichoric acid 
(Bauer and Wagner, 1991). Cichoric acid was first isolated from E. purpurea (Bauer and 
Wagner, 1991 ). Cichoric acid is abundant in the flowers and roots, and less present in the 
leaves and stems (Bauer et al., 1988). Alkylamides were first reported in the roots of E . 
. angustifolia by Jacobson (1954), who isolated a polyunsaturated alkylamide. Hyun-Ock et 
al. (2000) showed Echinacea purpurea roots contained higher concentrations of alkylamides 
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than leaves. They also showed that air-drying was the best method for drying leaves to 
preserve the alkylamide levels in E. purpurea, over freeze-drying and vacuum microwave 
drying. 
Immune activating 
The non-specific immune activating properties of Echinacea purpurea are well 
documented. The immunostimulatory properties of E. purpurea have been attributed to 
lipophilic alkylamides as well as the caff eic acid derivative, cichoric acid (Bauer and 
Wagner, 1991 ). Alkylamide fractions cause stimulation of phagocyte activity in vitro (Bauer 
et al., 1988, 1989). An alkylamide fraction from E. purpurea roots was shown by Wagner et 
al. (1989) to display anti-inflammatory activity in vitro. Schulte et al. (1967) isolated 
polyacetylene compounds with bacteriostatic activity in vitro from E. purpurea. Interferon-
like antiviral activity was shown by Orinda et al. (1973) who investigated the activity of 
Echinacin® against encephalomyocarditis virus and vesicular stomatitis in cultures of mouse 
cells. Echinacea root extracts of E. purpurea, E. angustifolia and E. pallida caused an 
increase in phagocytosis, with E. purpurea being most active (Bauer et al., 1989). Cichoric 
acid caused stimulation of phagocytosis in the in vitro granulocyte test (Bauer et al., 1989). 
Low concentrations of E. purpurea induced increased cytokine production by human 
peripheral blood macrophages in vitro (Burger et al., 1997). Most studies have demonstrated 
non-specific immune effects. Although, specific immunostimulatory effects have been 
shown in vivo. Antigen-specific immunoglobulin response was increased following 
treatment with E. angustifolia in rats (Rehman et al., 1999). The current information 
available suggests that immunostimulatory activity of Echinacea species depends on the 
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combined action of caffeic acid devrivatives and alkylamides. These components could act 
by non-specific or antigen-specific immunostimulatory mechanisms. 
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CHAPTER 3: EFFECT OF DIETARY ECHINACEA PURPUREA ON 
VIREMIA AND PERFORMANCE IN PRRSV-INFECTED NURSERY 
PIGS 
A paper submitted to the Journal of Animal Science 
J. H. Hermann*, M. S. Honeyman*2, J. J. Zimmermant, B. J. Thackert, P. J. Holden* 
and C. C. Changt 
*Department of Animal Science; tCollege of Veterinary Diagnostic and Production Animal 
Medicine, Iowa State University, Ames 50011 
ABSTRACT: The effect of diet on performance, viremia, and ontogeny of the humeral 
antibody response against porcine reproductive and respiratory syndrome virus (PRRSV) 
infection was evaluated in weaned pigs. In three replicates, weaned pigs (18 ± 1 d of age) 
from a PRRSV-naYve herd were randomly allotted to one of four pens (diets) in two rooms, 
each pen containing five pigs. Pigs (pens) began one of four dietary treatments 1 wk prior to 
inoculation with PRRSV: 1) basal diet plus carbadox (0.055 g/kg); 2) basal diet plus 
Echinacea 2% (2% of the total diet); 3) basal diet plus Echinacea 4% (4% of the total diet); 
and 4) basal diet composed of com, soybean meal, whey, and essential vitamins and 
minerals. Echinacea purpurea was purchased in powder form and determined by chemical 
analysis to contain 1.35% cichoric acid. Seven days after starting the diets ( d 7), all pigs in 
1The authors gratefully acknowledge support of this project by the Leopold Center for Sustainable 
Agriculture, Hatch Act funds, and State of Iowa funds; Bev Fowles for her work in serology, Dianne McDonald 
at LID IF for her patience throughout the trial, and employees at the swine nutrition fann, Sally Medford, Pat 
Horton, Linda Mosman, Trevor Lutz, and Richard Evans. Also, thanks to Brian Wheeler, John Gilbert, Arlie 
Penner, Nicole Will, Dennis Horter, Kurt Krumm, Colin Johnson, and Charlwit Kulchaiyawat for their help in 
data and sample collection. 
2Correspondence: (phone: 515-294-4621; fax: 515-294-6210; E-mail: honeyman@iastate.edu). 
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one room were intranasally inoculated with PRRSV isolate ATCC VR-2332 at a 
concentration of 104 tissue culture infectious dose (TCID) 50/ml. To monitor the effects of 
diet and PRRSV infection, body weight and blood samples were obtained from all pigs at 7-d 
intervals ( d 0 to d 42). Serum samples were analyzed for the presence of PRRSV and 
PRRSV-specific antibodies. All inoculated pigs became infected with PRRSV, and all 
uninoculated pigs remained free of infection. PRRSV-infected pigs had a lower percentage 
increase in body weight between d 7 to 42 compared with uninfected pigs (P < 0.06). 
However, no differences were obsereved between PRRSV-infected compared with 
uninfected animals with regard to body weight, ADG, ADFI, or G:F. Among animals 
receiving diets supplemented with Echinacea (treatments 2 and 3), no differences were 
observed in percentage increase in body weight, ADG, ADFI, and G:F ratio in either the 
PRRSV-infectedor -uninfected pigs. Among PRRSV-infected pigs, dietary Echinacea did 
not affect the rate or level of the ELISA-detectable antibody response d 7 to 42 or the level 
and duration of PRRSV in serum. Under the conditions of this study, dietary Echinacea did 
not reverse the growth-inhibiting effects of PRRSV, did not exhibit anti viral effects, and did 
not show any evidence of immune enhancing properties. 
Key Words: Echinacea, Pig, Growth, PRRSV, Viremia 
Introduction 
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Antimicrobial agents are used in food animals as therapy for an infection or, in the 
absence of disease, for the subtherapeutic purpose of growth promotion as measured by 
increased rate of gain and improved feed efficiency (Gorbach, 2001; Stahly et al., 1980). 
Increased interest in curbing antibiotic use to reduce antimicrobial resistance has led to a 
growing interest in alternative growth promoters. The use of herbal remedies or botanicals in 
swine diets has been proposed because of their natural stimulation of the immune system 
and/or enhanced growth performance. Extracts from Echinacea have been shown to have 
nonspecific immunostimulatory properties in vitro (Bauer and Wagner, 1991 ), including 
increased phagocytosis (Stotzem et al., 1992), increased cytokine production (Burger et al., 
1997), and natural killer cell activity (See et al., 1997). Rehman et al. (1999) showed an 
increase in primary and secondary IgG response in mice treated with Echinacea. 
Hypothetically, these immune enhancing properties of Echinacea could provide resistance to 
viral swine diseases such as porcine reproductive and respiratory syndrome virus (PRRSV) 
and assist in the control of secondary bacterial infections. A few scientific studies have 
assessed the efficacy ofEchinacea in vivo with varying results (Melchart et al., 1998; Grimm 
and Miiller, 1999; Turner et al., 2000). We lmow of no studies that have involved pigs as an 
animal model in assessing the efficacy of Echinacea as an immunostimulant, and work 
evaluating Echinacea as a possible growth promotant is limited (Holden and McKean, 2000). 
Our objective was to determine the effects of dietary Echinacea purpurea, with a 
defined chemical profile, on the growth performance, level of viremia, and ontogeny of 
antibody response in PRRSV-infected nursery-age pigs. 
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Materials and Methods 
Animals 
Three replicate trials involving a total of 120 pigs (average initial body weight of 8.46 
kg) were conducted at the Iowa State University Livestock Infectious Disease Isolation 
Facility (LIDIF), Ames, IA. All pigs were farrowed and reared at the Iowa State University 
Lauren Christian Swine Research and Demonstration Farm, Atlantic, IA . . Sows were 
vaccinated 2 wk before their expected farrowing date with Littergard-LTC (Clostridium 
perfringens type C/E.coli bacterin-toxoid, Pfizer, Inc., NY) and farrowed in crates. In each 
trial, 40 crossbred piglets from this PRRSV -free herd were weaned between 1 7 to 19 d of age 
and allotted to one of eight pens in two separate rooms (four pens per room) at the LIDIF. 
Pigs were allotted to balance for pig weight and litter source. Animal housing and care was 
conducted under supervision of the Iowa State University Committee on Animal Care (Log 
No. 6-1-4861-S), and in accordance with the "Guide for the Care and Use of Agricultural 
Animals in Agriculture Research and Teaching" (FASS, 1999). At birth, the pigs were tail 
docked, ear notched, teeth clipped, males castrated, and injected subcutaneously with 2 ml of 
iron dextran and 0.5 ml of ceftiofur sodium. On d 7, all pigs received a second injection of 1 
ml of ceftiofur sodium. At weaning all pigs received injections of 0.5 ml of ivermectin and 1 
ml of penicillin, were weighed and allotted, and then moved to their assigned treatment. One 
pig was removed from the experiment due to a locomotor injury, and one pig died prior to 
PRRSV inoculation due to intestinal torsion. The experimental design included three 
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replications of two rooms (PRRSV-positive and PRRSV-negative), four pens per room, five 
pigs per pen, and four dietary treatments. 
Body/feed weights and blood collection 
Pigs and feeders were weighed initially and at 7-d intervals (including a 7-d pre trial 
period) until completion of each 42-d trial. For each pen ADG and ADFI were calculated. 
Blood was collected from the anterior vena cava of each pig at 7-d intervals (including the 7 
d pre trial period). Blood sampling methods used were described by Straw et al. (1999). The 
blood was centrifuged at 2,000 x g for 10 min at 4°C. The serum was stored in Falcon 5-ml 
polystyrene round-bottom tubes (Becton Dickinson Labware, Franklin Lakes, NJ) at -20°C 
until tested. 
Housing 
The LIDIF is a bio safety Level 2 building. The environment in each room is strictly 
controlled (humidity 70%, temperature 26.6°C). The pigs were housed in an infected room 
or a non infected control room. Five pigs were penned on nursery decks (1.22 x 2.43 m) 
with plastic-slatted floors. Each pen had one nipple waterer and a four-hole Kane 




Pigs (pens) began one of four dietary treatments 1 wk prior to inoculation with 
PRRSV. The treatment diets were: 1) basal diet plus carbadox (0.055 g/kg); 2) basal diet 
plus Echinacea 2% (2% of the total diet); 3) basal diet plus Echinacea 4% (4% of the total 
diet); and 4) basal diet composed of com, soybean meal, whey, and essential vitamins and 
minerals (no additive). Four phases of each diet were fed to coincide with differing stages of 
growth. Ford 7 to 0, d Oto 7, d 7 to 26, and d 26 to 42, the pigs were fed diets 1, 2, 3, and 4, 
respectively (Table 1 ). All diets were in meal form, and the pigs were given ad libitum 
access to feed. Diets were formulated to meet or exceed nutritional requirements (NRC, 
1998). 
The gross energy ofEchinacea was determined to be 3,344 kcal/kg (adiabatic bomb 
calorimeter, Parr Instrument Company, Inc., Moline, IL). Using the gross energy value of 
Echinacea and values from the NRC (1998) and Ewan (1996), the diet was adjusted to 
compensate for the low energy of Echinacea. Soy oil was added with the Echinacea, and 
equal amounts of com were removed. The diets were formulated to be isolysinic and iso-
methioninic. The diets contained nutrient concentrations that met or exceeded the estimated 
nutrient requirements of nursery pigs (NRC, 1998). Feeding mats (0.42 x 0.77 m) were 
placed in front of the feeders for the pre trial period. All pigs were fed diet 1 in the self-
feeders with additional feed on the nursery mats. Decreasing amounts of feed were placed on 
the mats until they were removed on d O. Wasted feed was minimal and not recorded. 
Certified organic Echinacea purpurea root was used for the presumed 
immunostimulatory activity of the caffeic acid derivative, cichoric acid (Bauer et al., 1989). 
Echinaceawas fed before inoculation with PRRSV until the end of the 42-d trial to allow for 
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possible effects on immune function to be observed. Three-year-old plants were harvested in 
September, and the root was dried with forced air to a moisture content of 9% (Nature's 
Cathedral, Inc., Blairstown, IA). The root was ground and sifted to a powder, then mixed 
with basal diets and fed. The treatment levels of2 and 4% Echinacea were chosen based on 
preliminary work at Iowa State University (Holden and McKean, 2000). Determination of 
phenolics in Echinacea was performed by Alpha Laboratories Division (Petaluma, CA). 
High-pressure liquid chromatography was used to determine the content of caftaric acid, 
chlorogenic acid, cichoric acid, and echinacoside in the dried powdered Echinacea purpurea 
root. The final results are expressed as a percentage of the total components in the material 
analyzed. The Echinacea contained 0.39% caftaric acid, 0.01 % chlorogenic acid, less than 
0.01 % echinacoside, and 1.35% cichoric acid. 
Virus preparation 
A clone of North American prototype PRRSV isolate ATCC VR-2332 (American 
Type Culture Collection, Manassas, VA) (Benfield et al., 1992; Collins et al., 1992) that had 
been passaged in pigs for 67 d was used. The virus was propagated on MARC-145 cells, a 
clone of the African monkey kidney cell line MA-104 considered highly permissive to 
PRRSV (Kim et al., 1993). The concentration of 104 TCID50/ml of the cloned virus was 
adjusted for the challenge virus. Pigs exposed to PRRSV were intranasally inoculated on d 7 
with 2 ml (I mVnaris) of clarified virus supernatant. To guarantee the immune system was 
developed, pigs were inoculated with PRRSV later than d 21 of age (Varley, 1995). 
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Virus titration 
A microtitration infectivity assay was performed to estimate the concentration of 
PRRSV in serum samples collected over time from inoculated pigs. Samples were serially 
10-fold diluted (lo-0 to 10-6) in culture medium. One hundred microliters of each dilution 
was added to three wells of a 96-well microtitration plate (Coming, Inc., Corning, NY) 
containing 24-h-old confluent MARC-145 cell monolayers. Inoculated cells were incubated 
at 37°C in a 5% CO2 humidified incubator. Each sample was run in duplicate. The cells 
were monitored daily for cytopathic effect (CPE) for up to 7 d. If CPE was not evident, the 
cells were fixed with 80% acetone, dried, stained with fluoroisothiocyanate-conjugated 
monoclonal antibody (Mab) specific for the N protein of PRRSV (Mab SDOWI 7, Rural 
Technologies, Brookings, SD), and visualized with fluorescence microscopy. The presence 
of PRRSV was based on the visualization of virus-specific CPE and/or fluorescence reaction. 
Virus titers were determined using the method described by Reed and Muench (1938) and 
expressed as TCID5o/ml. Serum antibody titers confirmed that the pigs were PRRSV naive at 
weaning and prior to virus challenge. 
Enzyme-linked immunosorbent assay 
A commercial ELISA kit (Herdchek Porcine Reproductive and Respiratory Syndrome 
Virus Antibody Kit, IDEXX Laboratories, Westbrook, ME) was used to detect PRRSV-
specific antibody in serum samples by following the procedures recommended by the 
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manufacturer. A sample was classified as positive for PRRSV antibody if the sample-to-
positive (SIP) ratio was equal to or greater than 0.4. 
Data analysis 
Average daily gain, ADFI, feed efficiency (G:F), PRRSV-speci:fic antibody titers, and 
serum PRRSV titers were calculated. Everitt (1995) suggests an approach to the analysis of 
repeated observations involving the use of summary measures. The summary measure of 
growth data for dietary treatments is percentage gain, defined as [(end weight- start weight) 
/ start weight] x 100. The intervals analyzed were d Oto 42, d 7 to 42, and d 21 to 42. 
Interval selection was based on the fact that on d 7 the pigs were challenged with PRRSV, 
and on d 21 the pigs ELISA serum-to-positive ratios were positive for PRRSV antibodies. 
Data were analyzed as a complete randomized block design by analysis of variance 
techniques using the general linear model {GLM) of SAS (SAS Insttitute, Inc., Cary, NC). 
The pig was considered the experimental unit for absolute weights, ADG, PRRSV-speci:fic 
antibodies, and serum virus concentrations. The pen was used as the experimental unit for 
ADFI and G:F ratio. Pig weight at d O was used as a covariate when analyzing pig 
performance. The error terms were replication x PRRS, replication x diet, diet x PRRS, and 
replication x diet x PRRS. Data were reported as least square means. 
Results and Discussion 
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Growth performance 
Pigs negative for PRRSV had a higher percentage increase in body weight than 
PRRSV-positive pigs d 7 to 42 (P < 0.06) following challenge with PRRSV on d 7 (Table 2). 
Thus, PRRSV inhibited growth of infected animals when compared with healthy animals 
over time. However, PRRSV status had no effect on individual pig body weight, ADG, or 
G:F ratio (Tables 3, 4, 5). Summary growth data expressed as percentage increase in body 
weight showed no differences ford Oto 42 and d 21 to 42. 
For the PRRSV-negative pigs the percentage increase in body weight of individual 
pigs did not differ between dietary treatments (Table 6). Feeding Echinacea to PRRSV-
negative pigs had no effect on individual pig body weight, ADG, ADFI, or G:F ratio when 
compared with either control or carbadox treatments (Table 7). Feeding high levels of 
Echinacea apparently had no effect on feed intake. Feeding carbadox had no effect on 
individual pig body weight, ADG, ADFI, or G:F ratio when compared with control 
treatment. Pigs fed diets supplemented with Echinacea performed comparably to pigs fed 
diets supplemented with carbadox on growth performance. The growth effects of carbadox 
were possibly not observed due to the high health status, low antigen exposure, and the near 
ideal environment (Coffey and Cromwell, 1995; Weber et al., 2001) effects ofEchinacea 
may not have been seen for the same reason. 
Within PRRSV-positive pigs the percentage increase in body weight of individual 
pigs did not differ between dietary treatments d O to 42 or d 7 to 42 (Table 8). Echinacea 4% 
had a higher percentage gain when compared with carbadox d 21 to 42 (P < 0.07). Feeding 
Echinacea to PRRSV-positive pigs had no effect on individual pig body weight, ADG, ADFI, 
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or G:F ratio when compared with carbadox and control treatments (Table 9). Diets 
supplemented with carbadox had no effect on individual pig body weight, ADG, ADFI, or 
G:F ratio. 
Viremia and serum antibody response 
Echinacea has been shown to increase IgG levels in rats (Rehman et al., 1999). 
However, no statistically significant differences were detected among the dietary treatments 
in level ELISA-detectable antibody response, number of pigs positive for PRRSV antibody 
by time, and level or duration of PRRSV viremia (Tables 10, 11, 12, 13). 
Implications 
Results of this study indicate that, the Echinacea purpurea used in this study (0.39% 
caftaric acid, 0.01 % chlorogenic acid, less than 0.01 % echinacoside, and 1.35% cichoric 
acid) and fed as 2% or 4% of the basal diet did not augment the antigen-specific antibody 
response to PRRSV, inhibit virus replication, or improve elimination of virus from nursery-
age pigs. Further work is needed to identify the potential role ofEchinacea as a possible 
antiviral or immune enhancing compound. 
Echinacea purpurea used in this study was not an effective alternative to traditional 
growth promotants currently used for nursery pigs. However, due to ideal environment 
conditions and low antigen exposure there is not convincing evidence to rule out Echinacea 
purpurea as a possible growth promotant. 
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a Contributed per kilogram of diet: 13,200 IU of vitamin A, 3,300 IU of vitamin D3, 66 IU of 
vitamin E, 19.8 g of riboflavin, 52 mg of d-pantothenic acid, 100 mg of niacin, and 60 µg of 
vitamin B12-
b Contributed per kilogram of diet: 11 ,000 IU of vitamin A, 2,750 IU of vitamin D3, 55 IU of 
vitamin E, 16.5 g ofriboflavin, 43.3 mg of d-pantothenic acid, 83.3 mg of niacin, and 55 µg 
of vitamin B12. 
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c Contributed per kilogram of diet: 9,900 IU of vitamin A, 2,475 IU of vitamin D3, 49.5 IU of 
vitamin E, 14.9 g of riboflavin, 39 mg of d-pantothenic acid, and 75 rrig of niacin, and 49.5 
µg of vitamin B12. 
d Contributed in part per million of diet: Zn, 150.0, Fe, 175.0, Mn, 60.0, Cu, 17.6, and I, 2.0. 
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Table 2. Effect of PRRSV status on percentage gain of body weighe 

















ay alues are least square means of the percentage gain of individual pigs. 
blnoculation with PRRSV at d 7. 
cdMean values within rows with a different superscript differ (P<0.06). 
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Table 3. Effects of PRRSV status on growth performance in nursery pigsa 
Day of experiment Treatment 
PRRSV Negative PRRSV Positive SEM 
0 8.44 8.48 0.22 
7 10.01 10.20 0.25 
14 12.91 12.89 0.30 
21 16.74 16.51 0.35 
28 21.19 20.75 0.41 
35 25.83 25.26 0.46 
42 30.74 30.64 0.54 
av alues are least square means of individual pig weights in kg. 
blnoculation with PRRSV at d 7. 
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Table 4. Effects of PRRSV status on average daily gain in nursery pigsa 
Wk of experiment Treatment 
PRRSV Negative PRRSV Positive SEM 
1 224 245 0.01 
2 413 384 0.01 
3 547 525 0.01 
4 636 597 0.02 
5 662 644 0.02 
6 701 682 0.02 
Total 530 513 0.01 
aValues are least square means of individual pig ADG (g/d). 
blnoculation with PRRSV at d 7. 
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Table 5. Effects of PRRSV status on gain:feed ratio in nursery pigsa 
Wk of experiment Treatment 
PRRSV Negative PRRSV Positive SEM 
1 465 520 0.02 
2 961 808 0.12 
3 969 990 0.09 
4 799 716 0.06 
5 519 511 0.02 
6 483 490 0.02 
aValues are least square means of individual pig G:F in g. 
blnoculation with PRRSV at d 7. 
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Table 6. Percentage gain of body weight for PRRSV-negative pigsa 
Day of experiment Dietary treatment 
Carbadox Control Echinacea Echinacea SEM 
2% 4% 
0-42 261.1 276.5 266.3 280.1 13.1 
7-42 201.9 220.2 212.6 211.8 9.1 
21-42 77.8 86.4 86.7 87.4 3.1 
aValues are least square means of the percentage gain6 of individual pigs. 
bpercentage gain= [ end weight - start weight/ start weight] x 100. 
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Table 7. The effects of feeding Echinacea purpurea on growth performance in PRRSV-
negative nursery pigs 
Dietary treatment 
Item Carbadox Control Echinacea Echinacea SEM 
2% 4% 
No of pigs 15 13 15 15 
Initial age, d 17-19 17-19 17-19 17-19 
Final age, d 66-68 66-68 66-68 66-68 
Weight, kg 
Start 8.61 8.18 8.49 8.45 0.48 
Wkl 10.34 9.60 9.85 10.21 0.50 
Wk2 13.48 12.46 12.73 12.93 0.61 
Wk3 17.44 16.27 16.30 16.80 0.71 
Wk4 21.57 20.43 21.14 21.56 0.82 
Wk5 26.09 25.30 25.61 26.22 0.93 
Wk6 30.64 30.24 30.62 31.43 1.1 
ADG,g 
Wkl 246 181 194 250 0.03 
Wk2 443 367 411 389 0.03 
Wk3 569 490 521 553 0.03 
Wk4 589 533 680 679 0.04 
Wk5 645 624 638 674 0.05 
Wk6 650 607 716 736 0.05 
Total ADG, g 524 472 527 547 0.02 
ADFI, g 
Wkl 474 466 429 490 0.03 
Wk2 527 385 497 517 0.07 
40 
Table 7. ( continued) 
Wk3 690 479 603 628 0.10 
Wk4 956 621 832 881 0.07 
Wk5 1,284 1176 1,318 1,319 0.14 
Wk6 1,527 1322 1,485 1,470 0.15 
Total ADFI, g 910 741 861 884 0.04 
Gain:feed ratio, g/kg 
Wkl 510 388 454 507 0.05 
Wk2 848 953 888 779 0.28 
Wk3 858 1022 892 932 0.20 
Wk4 628 858 814 772 0.13 
Wk5 516 530 501 511 0.05 
Wk6 434 459 500 505 0.05 
Total G:F, g/kg 632 636 674 667 0.08 
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Table 8. Percentage gain of body weight for PRRSV-positive pigsab 
Day of experiment Dietary treatment 
Carbadox Control Echinacea Echinacea 
2% 4% 
0-42 254.7 263.8 262.9 264.7 
7-42 192.4 199.9 199.1 205.3 
21-42 76.5c 84.6d 80.6d 89.4d 
aValues are least square means of the percentage gain of individual pigs. 
bpercentage gain= (end weight - start weight/ start weight) x 100. 






Table 9. The effects of feeding Echinacea purpurea on growth performance in nursery pigs 
challenged with PRRSV 
Dietary treatment 
Item Carbadox Control Echinacea Echinacea SEM 
2% 4% 
No. of pigs 15 15 15 15 
Initial age, d 17-19 17-19 17-19 17-19 
Final age, d 66-68 66-68 66-68 66-68 
Weight, kg 
Start 8.30 8.49 8.65 8.50 0.48 
Wkl 10.08 10.19 10.48 10.08 0.50 
Wk2 12.79 12.62 13.46 12.74 0.61 
Wk3 16.53 16.37 17.25 16.16 0.71 
Wk4 20.72 20.45 21.62 20.23 0.82 
Wk5 24.62 25.06 26.08 25.32 0.93 
Wk6 28.86 30.04 30.83 30.45 1.08 
ADG,g 
Wkl 253 242 262 . 226 0.02 
Wk2 388 347 424 379 0.02 
Wk3 534 536 542 489 0.02 
Wk4 599 584 624 582 0.05 
Wk5 556 659 637 726 0.06 
Wk6 607 710 680 733 0.04 
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Table 9. ( continued) 
Total ADG, kg 489 513 528 522 0.02 
ADFI, g 
Wk 1 465 489 503 447 0.03 
Wk2 531 420 523 534 0.07 
Wk3 628 512 558 587 0.10 
Wk4 870 816 796 876 0.07 
Wk5 1,231 1,300 1,258 1,304 0.14 
Wk6 1,372 1,325 1,421 1,523 0.15 
Total ADFI, g 850 810 843 879 0.04 
Gain:feed ratio, g/kg 
Wk 1 544 496 525 515 0.05 
Wk2 755 897 834 738 0.28 
Wk3 909 1,015 1,025 876 0.20 
Wk4 687 715 794 671 0.13 
Wk5 457 516 507 565 0.05 
Wk6 454 540 483 483 0.05 
Total G:F, g/kg 634 719 696 641 0.08 
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Table 10. Serum PRRSV titera 
Day of experiment Treatment 
Carbadox Control Echinacea Echinacea SEM 
2% 4% 
14 3.11 2.85 2.50 2.50 0.33 
21 2.15 2.24 2.20 2.18 0.26 
28 0.97 0.88 0.80 1.11 0.26 
35 0.05 0.00 0.39 0.29 0.14 
42 0.00 0.02 0.17 0.02 0.06 
avalues are least square means of the log10 (TCID5o/mL) for individual pig samples. 
blnoculation with PRRSV at d 7. 
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Table 11. Enzyme-linked immunosorbent assay serum-to-positive ratiosa 
Day of experiment Dietary treatment 
Carbadox Control Echinacea Echinacea SEM 
2% 4% 
0 0.00 0.02 0.01 0.00 0.006 
7 0.00 0.00 0.00 0.01 0.004 
14 0.01 0.04 0.02 0.02 0.008 
21 0.67 0.79 0.46 0.47 0.157 
28 1.03 1.06 0.78 0.71 0.122 
35 1.47 1.49 1.25 1.19 0.109 
42 1.49 1.44 1.29 1.39 0.114 
aValues are least square means of the serum-to-positive ratios for individual pig 
samples. 
blnoculation with PRRSV at d 7. 
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Table 12. Number of pigs within treatment groups positive for PRRSV antibody 
Day of experiment Dietary treatmenta 
Carbadox Control Echinacea 2% Echinacea 4% 
0 0 0 0 0 
7 0 0- 0 0 
14 0 0 0 0 
21 10 9 6 6 
28 15 14 11 10 
35 15 15 15 14 
42 15 15 15 15 
an = 15 pigs for each dietary treatment. 
blnoculation with PRRSV at d 7. 
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Table 13. Number of pigs within treatment groups in which PRRSV was recovered from 
serum samples 
Day of experiment Dietary treatment 
Carbadox Control Echinacea 2% Echinacea 4% 
14 15 14 11 11 
21 14 14 14 12 
28 11 1 6 9 
35 2 0 3 3 
42 0 1 2 1 
an = 15 pigs for each dietary treatment. 
blnoculation with PRRSV at d 7. 
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GENERAL SUMMARY 
There is evidence that Echinacea in various forms can be used to stimulate the 
immune system. The increased use of Echinacea as an immunostimulant warrants the need 
for scientific evidence of a possible mechanism. Our experimental design served to explain 
possible mechanisms by examining antigen specific antibodies and non-specific effects 
through virus serum titers. Echinacea is not FDA regulated and chemical constituents can 
vary greatly by species, part of plant used, time harvested, and processing techniques. 
Therefore, a chemical profile of each plant must be defined in order to establish the 
compounds responsible for possible immunostimulatory properties. The Echinacea purpurea 
used in this study (0.39% caftaric acid, 0.01 % chlorogenic acid, less than 0.01 % 
echinacoside, and 1.35% cichoric acid) and fed as 2 % or 4 % of the basal ration did not 
stimulate antigen specific antibodies to PRRSV, inhibit virus replication, or improve 
elimination of virus from nursery pigs. Continued work is needed to identify the potential 
role of Echinacea as a possible antiviral or immunostimulatory compound. 
Due to antibiotic resistant strains of bacteria there has been increasing pressures to 
decrease the use of antibiotics as growth promotants. Consumer demand for natural and 
organic pork production has led to interest in alternative growth promotants. Preliminary 
work has showed that Echinacea did not effect feed intake and may enhance growth. The 
Echinacea purpurea used in this study (0.39% caftaric acid, 0.01 % chlorogenic acid, less 
than 0.01 % echinacoside, and 1.35% cichoric acid) and fed as 2 % or 4 % of the basal ration 
did not effect ADG, G:F ratio, ADFI, or percentage gain. This study indicates that Echinacea 
is not a viable option as a growth promotant. 
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